Oppenheimer Reiterates Outperform Rating for Veru (NASDAQ:VERU)

Oppenheimer restated their outperform rating on shares of Veru (NASDAQ:VERU) in a report published on Monday, Benzinga reports. The firm currently has a $5.00 price target on the stock, down from their previous price target of $7.00.

Other equities analysts have also recently issued research reports about the company. HC Wainwright reaffirmed a buy rating and issued a $2.00 price target on shares of Veru in a report on Thursday, February 8th. Raymond James assumed coverage on Veru in a report on Thursday, March 28th. They set an outperform rating and a $3.00 price target for the company.

Veru Stock Down 7.6 %

Shares of NASDAQ:VERU opened at $1.16 on Monday. The business has a 50 day moving average price of $0.72 and a 200 day moving average price of $0.75. Veru has a twelve month low of $0.36 and a twelve month high of $1.92. The company has a market cap of $169.80 million, a price-to-earnings ratio of -1.55 and a beta of -0.21.

Veru (NASDAQ:VERU) last announced its earnings results on Monday, April 1st. The company reported ($0.09) earnings per share for the quarter. The business had revenue of $2.14 million for the quarter. Veru had a negative net margin of 405.04% and a negative return on equity of 257.92%. Analysts anticipate that Veru will post -0.32 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Swiss National Bank boosted its position in shares of Veru by 7.2% in the 1st quarter. Swiss National Bank now owns 151,000 shares of the company’s stock worth $729,000 after purchasing an additional 10,100 shares during the last quarter. Raymond James & Associates raised its stake in shares of Veru by 4.9% in the 1st quarter. Raymond James & Associates now owns 85,100 shares of the company’s stock valued at $411,000 after purchasing an additional 4,000 shares during the period. Bank of New York Mellon Corp increased its position in shares of Veru by 2.9% in the first quarter. Bank of New York Mellon Corp now owns 215,790 shares of the company’s stock valued at $1,042,000 after acquiring an additional 6,161 shares during the last quarter. Rhumbline Advisers increased its position in shares of Veru by 3.6% in the first quarter. Rhumbline Advisers now owns 68,654 shares of the company’s stock valued at $332,000 after acquiring an additional 2,410 shares during the last quarter. Finally, Blair William & Co. IL increased its position in shares of Veru by 4.8% in the first quarter. Blair William & Co. IL now owns 329,925 shares of the company’s stock valued at $1,594,000 after acquiring an additional 15,000 shares during the last quarter. 47.16% of the stock is currently owned by institutional investors.

Veru Company Profile

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.